Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.

about

Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus.

P2860

Q47567913-B5F334CF-136E-44E6-9177-93AA3F2E66AC

P2860

Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.

Item

http://www.wikidata.org/entity/Q36656331

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Exenatide Treatment Causes Sup ...... Test in Obese Diabetic Women.

@ast

Exenatide Treatment Causes Sup ...... Test in Obese Diabetic Women.

@en

type

Item

label

Exenatide Treatment Causes Sup ...... Test in Obese Diabetic Women.

@ast

Exenatide Treatment Causes Sup ...... Test in Obese Diabetic Women.

@en

prefLabel

Exenatide Treatment Causes Sup ...... Test in Obese Diabetic Women.

@ast

Exenatide Treatment Causes Sup ...... Test in Obese Diabetic Women.

@en

P1476

Exenatide Treatment Causes Sup ...... l Test in Obese Diabetic Women

@en

P2093

Deniz Sigirli

http://www.w3.org/2001/XMLSchema#string

Figen Topyildiz

http://www.w3.org/2001/XMLSchema#string

Gurcan Kisakol

http://www.w3.org/2001/XMLSchema#string

Metin Guclu

http://www.w3.org/2001/XMLSchema#string

Sinan Cavun

http://www.w3.org/2001/XMLSchema#string

Sinem Kiyici

http://www.w3.org/2001/XMLSchema#string

P2860

A role for ghrelin in the central regulation of feeding

Ghrelin acts in the central nervous system to stimulate gastric acid secretion.

Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.

Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans.

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

Ghrelin stimulates gastric acid secretion and motility in rats.

Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans.

The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management.

P304

1309502

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2016/1309502

http://www.w3.org/2001/XMLSchema#string

P478

2016

http://www.w3.org/2001/XMLSchema#string

P50

Zulfiye Gul

P577

2016-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

293332464

http://www.w3.org/2001/XMLSchema#string

P698

26998491

http://www.w3.org/2001/XMLSchema#string

P921

Adipositas

P932

4779845

http://www.w3.org/2001/XMLSchema#string

Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.

about

P2860

P2860

Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P932